HIV VACCINES AND MICROBICIDES RESOURCE TRACKING WORKING GROUP

Download the report From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape (PDF).

The US remains main contributor, call for broader global partnering

In 2012, reported funding for HIV prevention research and development (R&D) increased by six percent compared to 2011, reaching a total of US$1.31 billion. However, a significant portion of this increase is likely due to improved reporting by several donors. The actual increase is thought to be moderate, and the overall funding prospect is essentially one of stagnation.

The US remained the largest public-sector investor overall, spending a total of US$925 million in 2012—70 percent of the total investment in HIV prevention R&D. European public-sector investment totaled US$86 million, other governments invested US$69 million, philanthropic organizations invested US$203 million and the commercial sector invested US$34 million.

A more diverse global cadre of funders, both involved in 
and dedicated to advancing HIV prevention R&D, would better utilize global resources and represent a powerful force in the effort to bring down new infections. An expanded and more diversified investment base could draw on nontraditional sources, such as emerging economies and countries hosting clinical and other HIV prevention research, along with recommitted member states of the Organization for Economic Co-operation and Development (OECD), whose support for HIV prevention R&D has waned over the past several years. 

103



The foundation for such efforts is in place. The HIV prevention field has worked to catalyze innovative partnerships across the public, private, philanthropic and academic sectors in order to capitalize on available resources and advance promising pipeline candidates. Still, greater efficiency and clarity in directing funding toward the most effective programs, and assuring that such investments are complementary rather than duplicative, would go a good distance toward optimizing investments across all areas of research. Always a desirable state of affairs, such participation, partnering, and shared processes for managing HIV prevention R&D must now become even more rigorous as economic and budgetary pressures become features of the global health research landscape that are unlikely to change in the near future.

124

All Content © 2000 - 2014 HIV Resource Tracking. Website Maintained by Progress Technology, Inc.
Log In / Administration